Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Dong-A Wins Approvals From Otsuka, GSK For Split Into Holding Company

This article was originally published in PharmAsia News

Executive Summary

Dong-A Pharmaceutical is pushing to create a favorable environment for a temporary shareholder meeting on Jan. 28, though the third-largest shareholder, the National Pension Service, is opposed to a proposal to float a holding company.

You may also be interested in...



Korea Allows Sales Of OTC Products In Supermarkets July 21, But Distribution Remains A Challenge

SEOUL - South Koreans are expected to be able to purchase 48 new over-the-counter products at supermarkets and conveniences stores, previously only available at pharmacies, beginning July 21, but consumers found that companies need more time to allow for the expanded distribution and manufacturing

Dong-A Enrolls GSK Korea General Manager On Board Of Directors; GSK Says Move Will Strengthen Alliance, Not Influence

SEOUL - Korea's leading pharma Dong-A Pharmaceutical Co. Ltd. placed GlaxoSmithKline PLC's Korea General Manager Kim Jin-ho on its nine-member board of directors in a follow-up action to GSK's acquisition of a 9.9% stake in Dong-A in May 2010

Korea's Health Ministry Gets In The Act To Generate Korean Innovation For U.S. Markets

SEOUL - South Korea's Ministry of Health and Welfare has selected 21 Korean pharmaceutical manufacturers and 17 medical equipment firms to support these companies in the development of globally competitive new drugs, marketing efforts and U.S. FDA approvals needed for their advancement into the U.S. market

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC082507

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel